Literature DB >> 8180414

The endogenous cyclic AMP antagonist, cyclic PIP: its ubiquity, hormone-stimulated synthesis and identification as prostaglandylinositol cyclic phosphate.

H K Wasner1, U Salge, M Gebel.   

Abstract

This report shows that the cyclic AMP antagonist cyclic PIP is present in all organs and tissues of the rat so far examined: brain, heart, lung, intestine, kidney, liver, spleen, skeletal muscle and fat. The synthesis of cyclic PIP is stimulated by insulin or noradrenaline (alpha-adrenergic action) in a dose-dependent fashion. Increasing cyclic PIP synthesis with increasing insulin concentrations matches the insulin receptor binding curves. Cyclic PIP levels in blood serum remain low after hormonal stimulation and no cyclic PIP can be detected in urine. As an indication of its ubiquity, cyclic PIP was even detected in yeast. Prostaglandin E (as shown by incorporation of [3H]PGE into cyclic PIP and demonstration of a constant specific activity), myo-inositol (as shown by acid hydrolysis of the dephosphorylated cyclic PIP and mass spectrometric identification of the products) and one phosphate (as shown by the ionic nature of cyclic PIP and its inactivation by phosphodiesterase plus phosphatase) are components of cyclic PIP. Chemical derivatization experiments of cyclic PIP suggest the phosphate to be bound to myo-inositol and the myo-inositol phosphate to the prostaglandin E by its C15-hydroxyl group.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8180414     DOI: 10.1007/bf00569933

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  61 in total

1.  Preparation of a liver plasma membrane with an adrenalin-responsive adenylyl cyclase after inhibition of prostaglandin synthesis by indomethacin.

Authors:  H K Wasner
Journal:  FEBS Lett       Date:  1976-12-15       Impact factor: 4.124

Review 2.  Inositol phospholipids and cell surface receptor function.

Authors:  R H Michell
Journal:  Biochim Biophys Acta       Date:  1975-03-25

3.  Hormonal regulation of pyruvate dehydrogenase.

Authors:  R L Jungas
Journal:  Metabolism       Date:  1971-01       Impact factor: 8.694

4.  Regulation of insulin receptors and insulin responsiveness in 3T3-L1 fatty fibroblasts.

Authors:  F A Karlsson; C Grunfeld; C R Kahn; J Roth
Journal:  Endocrinology       Date:  1979-05       Impact factor: 4.736

5.  [Animal experiments on the effect of prostaglandin E1 on fat and carbohydrate metabolism].

Authors:  E Böhle; H Rettberg; H H Ditschuneit; R Döbert; H Ditschuneit
Journal:  Verh Dtsch Ges Inn Med       Date:  1967

6.  Improved evaluation of binding of ligands to membranes containing several receptor-subtypes.

Authors:  B Ehle; H Lemoine; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-10       Impact factor: 3.000

Review 7.  Mechanisms involved in alpha-adrenergic phenomena.

Authors:  J H Exton
Journal:  Am J Physiol       Date:  1985-06

8.  Effects of prostaglandin E2 inhibition on norepinephrine plasma levels after adrenergic stimulation in man.

Authors:  G G Neri Serneri; G Masotti; S Castellani; L Scarti; A Morettini; R Sciagrà; M Mannelli
Journal:  Adv Prostaglandin Thromboxane Leukot Res       Date:  1983

9.  Biosynthesis of cyclic AMP antagonist in hepatocytes from rats after adrenalin- or insulin-stimulation. Isolation, purification and prostaglandin E-requirement for its synthesis.

Authors:  H K Wasner
Journal:  FEBS Lett       Date:  1981-10-26       Impact factor: 4.124

10.  Characterization of a pyruvate dehydrogenase activator released by adipocyte plasma membranes in response to insulin.

Authors:  J R Seals; M P Czech
Journal:  J Biol Chem       Date:  1981-03-25       Impact factor: 5.157

View more
  3 in total

1.  Biosynthesis of the endogenous cyclic adenosine monophosphate (AMP) antagonist, prostaglandylinositol cyclic phosphate (cyclic PIP), from prostaglandin E and activated inositol polyphosphate in rat liver plasma membranes.

Authors:  H K Wasner; M Lessmann; M Conrad; H Amini; E Psarakis; A Mir-Mohammad-Sadegh
Journal:  Acta Diabetol       Date:  1996-07       Impact factor: 4.280

2.  Indomethacin treatment causes loss of insulin action in rats: involvement of prostaglandins in the mechanism of insulin action.

Authors:  H K Wasner; S Weber; H J Partke; H Amini-Hadi-Kiashar
Journal:  Acta Diabetol       Date:  1994-12       Impact factor: 4.280

Review 3.  Metformin's Mechanism of Action Is Stimulation of the Biosynthesis of the Natural Cyclic AMP Antagonist Prostaglandylinositol Cyclic Phosphate (Cyclic PIP).

Authors:  Heinrich K Wasner
Journal:  Int J Mol Sci       Date:  2022-02-16       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.